Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07516444

VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)

Pivotal trial to evaluate the safety and clinical efficacy of the VDyne System for the treatment of symptomatic severe or greater tricuspid regurgitation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

The clinical trial is a prospective, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the VDyne Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation. Subjects will be followed at discharge, 30 days, 3 months, 6 months and annually through 5 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old
  • Subject is willing and able to comply with all study evaluations and provide consent
  • Subject must agree not to participate in any other clinical trial for a period of one year following index procedure
  • New York Heart Association (NYHA) Functional Class II, III, or IV and ambulatory
  • At least severe symptomatic tricuspid regurgitation.
  • Despite adequate and Optimized Medical Therapy (OMT), subject has signs and symptoms from TR, or prior heart failure hospitalization from TR
  • Heart team determines that the subject is appropriate for transcatheter tricuspid valve replacement
  • Functional and/or degenerative TR graded as at least severe

Exclusion criteria

  • Subject unable or unwilling to comply with study required testing and follow-up visits
  • Subject is currently participating in another clinical trial (drug, biologic, or device) that has not yet completed its primary endpoint or is likely to interfere with this study
  • Pregnant, lactating subjects, and /or those who plan pregnancy in the period up to one year following index procedure.
  • Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anticoagulation, etc.) which cannot be adequately managed medically
  • Life expectancy ≤12 months due to non-cardiac comorbidities
  • Current IV Drug user (must be free from drug abuse for ≥1 year)
  • Subject unable or unwilling to provide written, informed consent before study enrollment
  • Tricuspid valve anatomy (cardiac and vascular) that is not suitable for the VDyne System
  • Hypersensitivity to metals (such as nickel or titanium)
  • Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne valve (e.g., valve replacement, edge to edge repair, etc.)
  • Severe valvular heart disease using established echocardiographic criteria requiring intervention other than the tricuspid valve
  • Known significant intracardiac shunt (e.g., septal defect).
  • Cerebrovascular accident (stroke, TIA) within 90 days of treatment procedure
  • Severe lung disease (severe COPD) or continuous use of home oxygen or oral steroids
  • Acute myocardial infarction (AMI) within 30 days of SSC determination of eligibility
  • Leukopenia, chronic anemia (Hgb < 9 g/dL), current thrombocytopenia (platelets <70/mcL), history of bleeding diathesis, or coagulopathy
  • Unwilling to receive blood products
  • Deep vein thrombosis and/or pulmonary embolism in the last 6-months

Treatment and study plan

Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne System

Device

Subjects will undergo TTVR procedure with VDyne device and will continue to be managed on Optimal Medical Therapy (OMT).

Other names: Transcatheter Tricuspid Valve Replacement

Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System

Device

Subjects will undergo TTVR procedure with Edwards EVOQUE device and will continue to be managed on Optimal Medical Therapy (OMT).

Other names: Transcatheter Tricuspid Valve Replacement

Primary outcomes

  1. Composite of major adverse events (MAEs)

    Time frame: 30 days post-procedure

    Composite of major adverse events consist of the following:

    • Cardiovascular mortality
    • Stroke
    • Life-threatening bleeding
    • Major vascular complications
    • Major cardiac structural complications
    • Stage 2 or 3 acute kidney injury
    • Myocardial infarction or coronary ischemia
    • Device-related obstruction of forward flow
    • Device-related pulmonary embolism
    • Any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention
  2. Composite of all-cause mortality, heart failure hospitalization, or non-elective tricuspid valve reintervention

    Time frame: 12 months post-procedure

    All-cause mortality, heart failure hospitalization and non-elective tricuspid valve reintervention will be adjudicated by a Clinical Events Committee.

  3. Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: 12 months post procedure

    The Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. From 23-items, the Overall Summary Score (OSS) will be calculated. In the OSS, each of the 23 items are converted onto a 0 to 100 scale using this formula: (Raw score - Minimum Raw Score)/(Maximum Raw Score - Minimum Raw Score) * 100. Then these are averaged across the 23 items. A score of 100 (the maximum score) would indicate maximum quality of life relating to heart failure and a score of 0 (scale minimum) would indicate the worst possible quality of life relating to heart failure, with higher scores generally indicating higher quality of life.

  4. Change in Quality of Life (QOL) as measured by New York Heart Association (NYHA)

    Time frame: 12 months post procedure

    The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure by classifying patients in one of four categories based on their limitations during physical activity and in degree of shortness of breath and or angina pain. Class I is the least severe and Class IV is the most severe. The classes are:

    Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.

    Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.

    Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances. Comfortable only at rest.

    Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

Secondary outcomes

  1. All-Cause Mortality

    Time frame: At 12 months and 24 months

    Total number of deaths from any cause

  2. RVAD implantation or heart transplant

    Time frame: At 12 months and 24 months

    Total number of patients requiring Right Ventricular Assist Device (RVAD) implantation or heart transplant

  3. Tricuspid valve surgical or percutaneous intervention

    Time frame: At 12 months and 24 months

    Total number of non-elective tricuspid valve re-interventions

  4. Heart failure hospitalizations

    Time frame: At 12 months and 24 months

    Total number of patients with at least one hospital admission due to heart failure

  5. Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: At 12 months and 24 months

    The Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. From 23-items, the Overall Summary Score (OSS) will be calculated. In the OSS, each of the 23 items are converted onto a 0 to 100 scale using this formula: (Raw score - Minimum Raw Score)/(Maximum Raw Score - Minimum Raw Score) * 100. Then these are averaged across the 23 items. A score of 100 (the maximum score) would indicate maximum quality of life relating to heart failure and a score of 0 (scale minimum) would indicate the worst possible quality of life relating to heart failure, with higher scores generally indicating higher quality of life.

  6. Change in Quality of Life (QOL) as measured by New York Heart Association (NYHA)

    Time frame: 12 months

    New York Heart Association (NYHA) Classification at 6 months. The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure by classifying patients in one of four categories based on their limitations during physical activity and in degree of shortness of breath and or angina pain. Class I is the least severe and Class IV is the most severe. The classes are:

    Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.

    Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.

    Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances. Comfortable only at rest.

    Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

  7. Change in 6-Minute Walk Distance (6MWD)

    Time frame: At 12 months and 24 months

    Functional status improvement, as measured by 6-Minute Walk Test total distance walked. The 6-Minute Walk Test (6MWT) is a test that measures the total distance an individual can walk on a flat, hard surface in 6 minutes. It is commonly used to evaluate functional exercise capacity in patients with conditions including heart failure. The minimum score possible is 0, which would represent an inability to walk any distance. There is no maximum score, as a patient could theoretically walk any distance in 6 minutes though 800 meters considered the top reference range, which is what would be expected by elite athletes. Higher score indicate greater higher exercise capacity and lower scores indicate lower exercise capacity.

  8. Change in Echocardiographic Tricuspid Regurgitation (TR) grade from baseline using TransEsophageal Echocardiogram (TEE)

    Time frame: At 6 months, 12 months and 24 months post-implant compared to baseline

    Change in Tricuspid Regurgitation (TR) grade from baseline is measured. A 5-tier grading scheme will be used: mild, moderate, severe, massive and torrential. The change in TR grade is assessed using TransEsophageal Echocardiogram (TEE) imaging.

Study contacts

Contact information is provided by the study sponsor or research team.

Jeya Satheesh

CONTACT

[email protected]

952-686-8158

Vinny Podichetty

CONTACT

[email protected]

763-777-5969

Sponsors and collaborators

Lead sponsor

VDyne, Inc.

Industry

Registry information

Official study title

VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation

Acronym: TRIVITA

Important dates

Study start
2026
Primary completion
2029
Study completion
2036
First posted
Apr 8, 2026
Registry last updated
Apr 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.